NEW YORK, Sept. 12 /PRNewswire/ -- Atticus Capital LP does not support Genzyme Corporation's (GENZ) bid for AnorMED Inc. (ANOR), believing that it is not in the best interest of shareholders. "We think the Genzyme bid undervalues the company, and support the efforts of AnorMED and its advisors to seek better alternatives," stated an Atticus spokesman. Atticus Capital currently owns 9.1% of the outstanding shares of AnorMED. DATASOURCE: Atticus Capital LP CONTACT: Robert Coburn of Atticus Capital LP, +1-212-373-0800

Copyright